Is there any generic version of nirogacestat currently on the market?

Nirogacestat (nirogacestat) has not yet been officially launched as a generic drug globally. As a new gamma-secretase inhibitor developed by SpringWorks Therapeutics, nilogalstat was approved by the US FDA in November 2023 for the treatment of a rare tumor type - aggressive fibrous tumor (Desmoid tumor). It is the first targeted drug approved for this disease in the world. Because it is an innovative drug and is still within the patent protection period, only the original version of the drug is sold in the global market, and there are no legally marketed generic drugs.

According to the guidelines , after innovative drugs are approved by regulatory agencies such as the FDA or EMA, they usually enjoy market exclusivity for at least 5 to 10 years, during which generic drug manufacturers cannot obtain legal marketing approval. Nirogarestat’s patent protection covers its compound structure, synthesis methods and therapeutic uses. Several core patents have not yet expired, which means that the possibility of legal generic drugs being launched in the short term is low.

In addition, nirogalastat is currently commercialized in the United States, but has not completed the marketing registration process in China and other Asian regions. Because it is classified as an orphan drug and a drug for the treatment of rare diseases, the production threshold is high, the process is complex, and the market capacity is limited. This also requires generic drug companies to face multiple evaluations of technical difficulty, cost investment, and market return when entering. Therefore, even if generic drugs are technically feasible in the future, they still need to wait until the patent of the original drug expires before the relevant company applies for drug registration and goes through the bioequivalence certification process.

It is worth noting that there may be so-called"imitation versions" of Nilogacestat on some informal markets. However, most of these drugs are products that have not received regulatory approval, and there are problems with the quality, efficacy and safety of the drugs that cannot be guaranteed. If patients need treatment, they should give priority to obtaining original drugs through doctor's prescription and formal channels to ensure the safety of treatment.

Reference materials:https://www.drugs.com/mtm/nirogacestat.html